DelfaGLP-1 Atlas

Lead sponsor

Amsterdam UMC, location VUmc

8 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.

8

Trials led

0

Active

348

Total enrollment

2

Sites

Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.

Portfolio

How this sponsor's trials break down

Trials by phase

Phase 3
1
Phase 4
4
Not applicable
3

Trials by status

Completed
7
Unknown
1

Trials led

SAFEGUARD: Pleiotropic Effects of Incretin Based TherapiesBMI 25-40Ph 4Completed70
DECREASEBMI 27-40Ph 4Completed65
LIBRABMI ≤25not applicableCompleted50
Braini-ExBMI ≤25not applicableCompleted48
EXAMI—Ph 3Unknown40
ELIXIRSBMI ≥25Ph 4Completed40
Effects of Exenatide in Type 2 Diabetic Patients With Congestive Heart FailureHbA1c 6.5-10%Ph 4Completed27
PREDEXBMI ≤28not applicableCompleted8